Merck & Co.'s RNAi divestiture driven by focus on core businesses strategy
Merck & Co.’s divestiture of its RNA interference business (RNAi) was part of a strategy to cut $2.5bn and focus on core areas, according to its CEO.
Archives for January 14, 2014
McKesson's strategy unclear after $8.3bn Celsio takeover falls through
Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.
FDA marketing regulations include pharma employees’ Facebook
The US Food and Drug Administration (FDA) has drafted social media guidelines for pharmaceutical companies, regulating the Facebook and Twitter posts of employees who mention drug products.
Parexel ups guidance suggesting new business recovery in Q2
Parexel has raised its guidance for fiscal 2014 in a move that suggests the deals delayed in Q1 that spooked investors have started to come in.
Lonza to produce API for Pharmacyclics oral cancer drug
Lonza has extended a contract to manufacture the API for Pharmacyclics’ oncology drug Imbruvica following its recent regulatory approval.
MEPs back eHealth for Europe
MEPs say the European Union should adopt eHealth systems to improve efficiency and make shrinking national healthcare budgets go further.